Two points of interest:
1. The mean time for a 505 b pathway approval is approx 18 months. https://www.raps.org/regulatory-focus™/news-articles/2017/3/505(b)(2)-approval-pathway-not-necessarily-shorter-approval-times
2. Two external experts. Who are they? Obviously commercial in-confidence. It suggests that a company is in early stage negotiations to partner.
- Forums
- ASX - By Stock
- Ann: FDA meeting provides guidance for TPM/Oxymorphone patch
Two points of interest:1. The mean time for a 505 b pathway...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add POH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.0¢ |
Change
0.000(0.00%) |
Mkt cap ! n/a |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
POH (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online